임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

16건 표시

1상모집 중· Obesity & Overweight
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
리드: 대웅제약
상세 →NCT07539415
1상모집 중· Cancer
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
리드: 대웅제약
상세 →NCT07371104
1상모집 중· Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
리드: 대웅제약
상세 →NCT07267221
1상모집 중· Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
리드: 대웅제약
상세 →NCT07260851
해당없음모집 중· Hypertension
CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension
협력: 대웅제약
상세 →NCT07465549
단계 미표기모집 중· Stage 1 Hypertension
Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension
리드: 대웅제약
상세 →NCT07515599
1상모집 중· Healthy Subjects
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
리드: 대웅제약
상세 →NCT07144176
단계 미표기모집 중· Gastritis
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
리드: 대웅제약
상세 →NCT06948487
4상모집 중· Obesity and Type 2 Diabetes
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
협력: 대웅제약
상세 →NCT06782139
4상모집 중· Aortic Valve Stenosis
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
협력: 대웅제약
상세 →NCT05672836
1상모집 중· Autoimmune Diseases
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
리드: 대웅제약
상세 →NCT06736587
단계 미표기모집 중· Diabetes Mellitus, Type 2
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
리드: 대웅제약
상세 →NCT06647888
해당없음모집 중· Type 2 Diabetes
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
협력: 셀트리온, 종근당, 대웅제약
상세 →NCT06627322
해당없음모집 중· Acute Coronary Syndromes (ACS)
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
협력: 대웅제약
상세 →NCT07479056
4상모집 중· Type 2 Diabetes
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
협력: 대웅제약
상세 →NCT06399835
4상모집 중· Coronary Artery Disease
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
협력: 대웅제약, 한미약품, 유한양행
상세 →NCT05845489

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.